[CAS NO. 164204-38-0] Phosphoramidon Disodium
PRODUCTS SPECIFICATIONS [164204-38-0]
DESCRIPTION [164204-38-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 587.47 |
| Molecular Formula | C23H32N3Na2O10P |
| SMILES | O=C([C@@H](NC([C@@H](NP(O[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](O1)C)(O[Na])=O)CC(C)C)=O)CC2=CNC3=CC=CC=C23)O[Na] |
Summary
Phosphoramidon Disodium, a microbial metabolite , is a specific metalloprotease thermolysin inhibitor with an IC 50 of 0.4 μg/mL. Phosphoramidon Disodium also inhibits endothelin-converting enzyme ( ECE ), neutral endopeptidase ( NEP ), and angiotensin-converting enzyme ( ACE ) with IC 50 values of 3.5, 0.034, and 78 μM, respectively [1] [2] [3] .
IC50 & Target
|
Microbial Metabolite |
In Vitro
Phosphoramidon (1-500 μM; 30 min) inhibits ET-converting enzyme (ECE) activity in a dose-dependent manner in solubilized rabbit lung membranes [5] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Phosphoramidon (0.25 mg/kg per min; i.v.) suppresses the hypertensive effect of big endothelin-1 in rats
[4]
.
Phosphoramidon (1-30 mg/kg; i.v.; once) blocks the pressor activity of porcine big endothelin-1-(1-39) in rats
[5]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Sprague-Dawley rats [4] |
| Dosage: | 0.25 mg/kg per min |
| Administration: | Intravenous injection |
| Result: | Markedly suppressed the hypertensive effect of big endothelin-1. |
Appearance
Solid
Source
Streptomyces tanashiensis
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 100 mg/mL ( 170.22 mM ; Need ultrasonic)
DMSO : 100 mg/mL ( 170.22 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7022 mL | 8.5111 mL | 17.0221 mL |
| 5 mM | 0.3404 mL | 1.7022 mL | 3.4044 mL |
| 10 mM | 0.1702 mL | 0.8511 mL | 1.7022 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (170.22 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution
References
- [1] Umezawa S, , et al. A new microbial metabolite phosphoramidon (isolation and structure). Tetrahedron Letters, 1972, 13(1): 97-100.
- [2] Suda H, et al. A thermolysin inhibitor produced by actinomycetes: phosphoramidon. The Journal of antibiotics, 1973, 26(10): 621-623.
- [3] Kukkola PJ, et al. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.J CardiovascPharmacol. 1995;26Suppl 3:S65-8.
- [4] Matsumura Y, et al. Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1. Eur J Pharmacol. 1990 Aug 21;185(1):103-6.
- [5] McMahon EG, et al. Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):703-7.